[Corrections] Correction to Lancet Oncol 2024; 25: 317–25

Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol 2024; 25: 317–25—In this Article, in the sixth paragraph of the Results section, the second sentence should read as follows: “After independent central radiology review of the measurable disease response, the objective response rate at 24 weeks was zero (0%, 95% CI 0–10) of 34 patients in the 9 mg group and one partial response (2%, 0–14) of 39 patients in the 18 mg group.” This correction has been made to the online version as of June 24, 2024.